The Diabetes Research Institute Partners With iTolerance

The Diabetes Research Institute Partners With iTolerance

This year, the DRI entered into a new partnership with iTolerance, a Miami-based early-stage regenerative medicine company, with a promising new therapy in development for individuals with type 1 diabetes. The company’s lead platform technology, iTOL-100, is a...